Search results
2 No-Brainer Dividend Stocks to Buy in May
Motley Fool via Yahoo Finance· 6 days agoThe oncology market is known for its strong pricing power, with cancer drugs typically carrying high price tags and significant margins. While Pfizer's...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 2 days agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
Market Watch· 6 days agoMerck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to ...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 2 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 2 days agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 2 days ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 2 days agoThe trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab)...
Is Johnson & Johnson Stock A Better Pick Over Merck?
Forbes· 2 days agoAlthough Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over...
Merck stops skin cancer combination therapy testing in late-stage study
WSAU Wausau· 2 days ago(Reuters) -Merck has discontinued testing a combination of an experimental antibody-based drug and...
...Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab)...
Benzinga· 2 days agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that